



## For the promotion and recognition of excellence in orphan disease treatment research

The International Prize for Scientific Research was established in 2000 in memory of the Italian pharmaceutical entrepreneur Arrigo Recordati to carry on his legacy and to inspire scientists and researchers to make important discoveries benefiting people worldwide in the field of cardiovascular disease.

Arrigo Recordati, who passed away prematurely in 1999, strongly believed in the power of research to drive the development of the pharmaceutical industry and provide products beneficial to public health and individual wellbeing.

In the last ten years Recordati made the Rare Diseases field a health priority and increased its commitment worldwide through its dedicated subsidiaries (Orphan Europe and Recordati Rare Diseases) to research, develop and market a number of treatments for orphan diseases.

To reflect its commitment, Recordati decided that the 2019 Edition of The International Prize for Scientific Research Arrigo Recordati will be dedicated to the **promotion and recognition of excellence in orphan disease treatment research**. The winner project will receive a research grant of € 100,000.

### In honour of Arrigo Recordati

Arrigo Recordati believed research was the most powerful asset for the pharmaceutical industry.

He became head of the family business in 1951, at the age of 23, and transformed the family pharmaceutical laboratory founded in 1926 and employing 325 people into a global company listed on the Italian Stock Exchange since 1984.

Arrigo Recordati's remarkable life came to a premature end at the age of 71, in 1999.

### Recordati, a modern and dynamic international group



Recordati is an international pharmaceutical group dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, the Group has a staff of more than 4.100.



Recordati has grown constantly since 1926 thanks to the quality of its products and to the implementation of a decisive internationalization policy through a focused strategy of acquisitions and license agreements.



Recordati produces and promotes innovative medicines worldwide including both products for primary and specialty care therapies and treatments for rare diseases. In addition to the marketing of specialties generated by its original research, the Recordati group is the European partner of leading international pharmaceutical companies.



With subsidiaries in Europe, the U.S.A., Canada, some Latin American countries, in Japan and the Asia-Pacific regions, Russia and the Commonwealth of Independent States, Turkey and Tunisia, Recordati continues to strengthen its geographical presence.

### A growing commitment to the treatment of rare diseases

Recordati constantly enhances its therapeutic offering through the development of its product pipeline with a focus on rare diseases, mainly treatments for metabolic deficiencies of a genetic nature. The Group operates worldwide in a highly specialized market with a significant growth potential through its dedicated subsidiaries Orphan Europe and Recordati Rare Diseases in Usa.

### Previous editions and winners

**2001, first edition:** **Giuseppe Mancia**, Professor of Medicine, Chairman of the Department of Clinical Medicine, Prevention and Applied Biotechnologies at the University of Milan-Bicocca, Milan, (Italy), for his work in hypertension.

**2003, second edition:** **Jay N. Cohn** and **John K. Kjekshus** for their contribution to research in the field of heart failure. Jay N. Cohn is a Professor of Medicine, Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, (USA); John K. Kjekshus is a Professor of Medicine, Department of Cardiology, Rikshospitalet, University of Oslo, Oslo, (Norway).

**2005, third edition:** **Leonard A. Cobb**, **Peter J. Schwartz** and **Hein J.J. Wellens** for their contribution to research in the field of sudden cardiac death. Leonard A. Cobb is an Emeritus Professor, American College of Cardiology, Seattle, WA, (USA); Peter J. Schwartz is a Professor and the Chairman, Department of Cardiology, Policlinico San Matteo IRCCS, Pavia, (Italy), and Hein J.J. Wellens is Honoré Retired

Professor, University of Maastricht; Director of Arrhythmology, Interventional Electrophysiology and Cardiology, University of Maastricht, Maastricht, (The Netherlands).

**2007, fourth edition:** **Patrick W. Serruys**, Director of Interventional Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, (The Netherlands), for his outstanding achievements in the field of interventional cardiology and ischemic heart disease.

**2009, fifth edition:** **Valentin Fuster**, Director of Mount Sinai Heart, New York, N.Y., (USA), for his outstanding achievements in innovation and advances in imaging diagnostics in heart disease.

**2011, sixth edition:** **Lindsey D. Allan**, consultant at King's College, London, (United Kingdom), who was recognized as a pioneer in the field of foetal cardiology in the early '80s, and became a leading and worldwide respected expert in foetal cardiology throughout the past three decades for her outstanding achievements

in the field of interventional cardiology and ischemic heart disease.

**2013, seventh edition:** **Filippo Crea**, full Professor in Cardiology at Policlinico Agostino Gemelli, Rome, (Italy), for his outstanding achievements in the field of microcirculation and for keeping a consistent focus on clinical conditions related to dysfunction of the coronary microcirculation, identifying the clinical impact of events occurring in the coronary microcirculation, uncovering mechanisms, and pioneering therapeutic approaches.

**2015, eighth edition:** **John Valentine McMurray**, Professor of Medical Cardiology and convener for clinical research in the Institute of Cardiovascular & Medical Sciences at the University of Glasgow, Scotland, (United Kingdom) and to **Salim Yusuf**, Professor of Medicine, Executive, Director of the Population Health Research Institute (PHRI), McMaster University, Hamilton, (Canada) for their contribution in researching secondary prevention and risk reduction strategies for patients with cardiovascular diseases.

### 2019 Ninth Edition

International projects within the area of rare/orphan disease treatments in all therapeutic areas (except oncology, hematology and immunology) are eligible to apply as long the disease concerned has a prevalence of not more than 1 in 2000.

The 2019 Award is open to researchers of all nationalities who are not in any way directly affiliated with pharmaceutical or medical device companies. The 2019 Award will be given in recognition of ongoing research projects, for which preliminary results, such as proof-of-concept and proof-of-principle, have already been obtained.

Projects on orphan diseases which do not make use (or assess the potential) of an experimental treatment for a rare disease are not eligible for the Award.

### 2019 Award Calendar

**10<sup>th</sup>/09 - 15<sup>th</sup>/12/2018**

Submission of initial proposals

**15<sup>th</sup>/03 - 30<sup>th</sup>/04/2019**

Submission of Full Applications

**2<sup>nd</sup>-6<sup>th</sup>/09/2019**

Award Ceremony at SSIEM 2019, Rotterdam

For further information, nominations procedure and to submit an Application: [prize.recordati.it](http://prize.recordati.it)  
Contacts: [recordatiprize2019@recordati.com](mailto:recordatiprize2019@recordati.com)

### 2019 Jury

**Robert J. Desnick Ph.D, M.D.**

Dean for Genetic and Genomic Medicine, Professor and Chair Emeritus Department of Genetic & Genomic Sciences, Mount Sinai School of Medicine, New York, USA

**Francesco Emma M.D., Ph.D.**

Chief Department of Nephrology and Urology, IRCCS Children's Hospital Bambino Gesù, Rome, Italy

**Norio Sakai M.D., Ph.D.**

Child Healthcare and Genetic Science Laboratory, Division of Health Science, Osaka University Graduate School of Medicine, Osaka, Japan